Clinical significance of antiviral therapy for episodic treatment of herpes labialis: Exploratory analyses of the combined data from two valaciclovir trials

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 5, 2004, Pages 703-707

  Spruance, Spotswood L ^a   Hill, Joanne ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cold sores; HSV 1; Valaciclovir

Indexed keywords

PLACEBO; VALACICLOVIR;

ADULT; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEALING; HERPES LABIALIS; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNITED STATES;

ACYCLOVIR; ANTIVIRAL AGENTS; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; HERPES LABIALIS; HUMANS; VALINE;

EID: 2442644018     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh154     Document Type: Article

References (3)

1. Embil, J. A., Stephens, R. G. & Manuel, F. R. (1975). Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Canadian Medical Association Journal 113, 627-30.
2. Spruance, S., Jones, T., Blatter, M. et al. (2003). High-dose, short-duration, early valacyclovir therapy for the episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrobial Agents and Chemotherapy 47, 1072-80.
3. Spruance, S. L., Tyring, S. K., DeGregorio, B. et al. (1996). A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Archives of Internal Medicine 156, 1729-35.